Lilly to acquire Dermira for $1.1 billion, expanding its portfolio of Phase 3 medicines with the addition of lebrikizumab, an IL-13antibody being studied in Phase 3 for the treatment of moderate-to-severe atopic dermatitis Acquisition also includes QBREXZA, Dermira's medicated cloth for primary axillary hyperhidrosis
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.